CVS Health Corporation (NYSE: CVS) is identified as a cheap healthcare stock to buy heading into 2026. Bernstein SocGen Group raised the price target to $86.00, citing strong performance in the Aetna business unit despite challenges in the Pharmacy Benefit Manager segment. Aetna is seen as a growth engine, with potential for PBM growth alongside drug spend growth. RBC Capital maintains an Outperform rating and $93 price target, emphasizing CVS’s strong position as the market shifts towards rebate-free PBM models. CVS Health Corporation, based in Rhode Island, operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. While CVS presents investment potential, some AI stocks offer greater upside and less downside risk. Explore an undervalued AI stock in our free report.

Read more at Yahoo Finance: CVS Health Corporation (CVS) Sees Higher Price Target Despite PBM Pressures